Metabolic Disorders
| Focus: | Metabolic Disorders |
|---|---|
| Type: | database (supplied by e-mail as setup.exe file) |
| No. of deals: | 118 |
| No. of companies: | 116 |
| Years covered: | 1996 – 2011 |
| Price: | € 700 ex VAT (if applicable) |
| System requirements: | Windows 2000/Windows XP/Windows Vista/7 |
| Publisher: | PharmaPlus Consultancy B.V. |
Are you about to enter deal negotiations for your metabolic disorder therapeutic?
Use PharmaDeal Financials Metabolic Disorders to benchmark your next metabolic disorder deal
PharmaDeal Financials Metabolic Disorders
- Deal specifics on more than 110 metabolic disorder deals
- Deal making trends since 1996
- Approximately 90 different licensors
- Compound classes including antibodies, DPP-IV inhibitors, glucokinase activators, GLP-1 mimetics and TGR5 agonists
- 10% deals on drug delivery
- 29% phase I and phase II deals
- Over 75% deals with worldwide coverage
- Upfront preclinical products from USD 1 million to USD 50 million
- Equity from USD 0.6 million to USD 250 million
Each deal entry is categorized and searchable by licensor, licensee, indication, compound details, compound name, development stage (research-filed), geographical territory, potential deal size, upfront, total milestones-regulatory milestones-sales milestones payments, profit sharing, royalties on sales, research funding, equity and by year of deal establishment or any combination thereof.
Compound keywords
11beta-HSD1 inhibitors, 5HT2C agonists, AMP-activated protein kinase inhibitors, amylin analogues, antibodies, antisense, beta cell regeneration, biguanides, calcimimetics, cannabinoid antagonists, cell therapy, chemokine antagonists, Core 2 transferase inhibitors, DGAT-1 inhibitors, dopamine modulators, DPP-IV inhibitors, drug delivery, farnesoid X receptor modulators, gastrin analogues, ghrelin hormone agonists, glucagon-like peptide 1 mimetics, glucocorticoid receptor antagonists, glucokinase activators, GPCR modulators, herbal extracts, hormones, insulin, insulin analogues, insulin resistance modulators, insulin sensitizers, insulin signaling pathway activators, islet neogenesis, leptin modulators, lipase inhibitors, liver X receptor modulators, melanocortin receptor modulators, neuronal nicotinic receptor modulators, norephinephrine reuptake inhibitors, pepducins, peptide ligands, PPAR-agonists, pro-insulins, proteases, retinoids, SGLT2 inhibitors, siRNA, stapled peptide therapeutics, stearoyl-CoA desaturase inhibitors, stem cells, TGR5 agonists, thyroid hormone receptor ß agonists, vaccines, Y2 agonists
Companies included in database
Abbott Laboratories (Solvay Pharmaceuticals), Advinus Therapeutics, Aileron Therapeutics, Ajinomoto, Alantos Pharmaceuticals, Alizyme, Allergan, Alnylam Pharmaceuticals, Altea Therapeutics, Altus Pharmaceuticals, Amarantus Biosciences, Ambrx, Amgen (Tularik), Amylin Pharmaceuticals, Anchor Therapeutics, Aradigm Corporation, Arena Pharmaceuticals, Array BioPharma, AstraZeneca (MedImmune), Bayer, Bayhill Therapeutics, Biocompatibles International (CellMed), Biocon (Nobex Corporation), BioLineRx, Biovail Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst Biosciences, Celldex Therapeutics (Curagen Corporation), Chiesi Farmaceutici, CureDM, Daiichi-Sankyo Co., deCode Genetics, DepoMed, Diamyd Medical, Dr. Reddy’s Laboratories, Eisai Co, Eli Lilly & Company, Emisphere Technologies, Evotec (Develogen), Exelixis, Flamel Technologies, Forest Laboratories, Galapagos, Generex Biotechnology, GlaxoSmithKline, Glenmark Pharmaceuticals, Heptares Therapeutics, Hillcrest Therapeutics, Human Genome Sciences, Incyte Corporation, Inflazyme Pharmaceuticals (GlycoDesign), Insmed, Intercept Pharmaceuticals, Ipsen Pharma, Isis Pharmaceuticals, Japan Tobacco, Johnson & Johnson (Janssen Pharmaceuticals, Ortho McNeil), Karo Bio, LG Life Sciences, Ligand Pharmaceuticals, Living Cell Technologies, MacroGenics, Marina Biotech (MDRNA (Nastech Pharmaceutical Company)), Merck & Co, Merck Serono (Merck KGaA, Serono), Merrrion Pharmaceuticals, Metabasis Therapeutics, Metabolex, Mitsubishi Tanabe Pharma (Tanabe Seiyaku), Nautilus Biotech, Neurocrine Biosciences, Newron Pharmaceutials (Hunter-Fleming), Novartis, Novimmune, Novo Nordisk, NPS Pharmaceuticals, OctoPlus, Orexigen Therapeutics, OSI Pharmaceuticals (Prosidion), Osiris Therapeutics, Otsuka Pharmaceutical Co, Palatin Technologies, Pfizer (Pharmacia & Upjohn, Warner-Lambert, Wyeth), Phenomix Corporation, Phytopharm, Plexxikon, PPD (Syrrx), Probiodrug, Questcor Pharmaceuticals, Regeneron Pharmaceuticals, Rhythm Pharmaceuticals, Roche (Genentech), Sanofi (Aventis Pharma, Genzyme Corporation, Sanofi-Aventis), Santhera Pharmaceuticals, Seikagaku Corporation, Servier, Swedish Orphan Biovitrum (Biovitrum), Synis Pharma (Trega Biosciences), Taisho Pharmaceutical Co, Takeda Pharmaceutical Company (Millennium Pharmaceuticals), Targacept, Tercica, Teva Pharmaceutical Industries (Pliva, Ergo Science Corporation), Theratechnologies, Tolerx, Toyama Chemicals, Transition Therapeutics, TransTech Pharma, Vitae Pharmaceuticals, Wellstat Therapeutics Corporation, Xenon Pharmaceuticals, Xoma, Zealand Pharma, Zymogenetics
